Charlie Cao

See editorial on page 34; and related article on page 139. Background Vedolizumab, an antibody against α4β7 integrin, is indicated for ulcerative colitis (UC) and Crohn’s disease (CD). We investigated the time course of clinical response to vedolizumab in TNF-naive or -experienced patients. Findings Vedolizumab improved patient-reported symptoms of UC and CD as early as Week 2 of treatment, with continuing improvement through Week 6—especially for TNF-naive patients.

To evaluate the efficacy and safety of fasiglifam, an orally active G protein–coupled receptor 40 agonist, in combination with the dipeptidyl peptidase-4 inhibitor sitagliptin, in patients with type 2 diabetes inadequately controlled with diet/exercise (± metformin). In this randomized, double-blind, phase II study, 368 patients received once-daily placebo, sitagliptin 100?mg, fasiglifam 25 or 50?mg, or the combination of sitagliptin 100?mg plus fasiglifam 25 or 50?mg.

We've got loads of late night action flicks up ahead! Catch one any night this month. Here's the schedule: - Jaws (1975): July 1-4, 11 PM... - Shaft (1971): July 5-7, 10:30 PM - From Dusk Till Dawn (1996): July 8-11, 11 PM - Super Fly (1972): July 12-14, 10:30 PM - Fight Club (1999): July 15-18, 11 PM - Foxy Brown (1974): July 19-21, 10:30 PM - Full Metal Jacket (1987): July 22-25, 11 PM - Dirty Harry (1971): July 26-28, 10:30 PM - Scarface (1983): July 29-31, 11 PM Se mere